Gilgamesh pharmaceuticals stock
WebMar 24, 2024 · About Gilgamesh Pharmaceuticals. Gilgamesh is a pioneering mental health science-focused, biotechnology company. We have a disciplined focus on … WebOct 14, 2024 · Gilgamesh Pharmaceuticals has raised a total of $68.6M in funding over 7 rounds. Their latest funding was raised on Dec 15, 2024 from a Series B round. …
Gilgamesh pharmaceuticals stock
Did you know?
WebMay 6, 2024 · Quick Take: Gilgamesh Pharmaceuticals today announced the closing of a $27 million Series A round of funding led by Prime Movers Lab. In addition to Prime Movers Lab, investors included the Noetic … WebGilgamesh's AI-powered behavioral and imaging driven platform is accelerating and optimizing the development of our new chemical entities (NCEs) which offer improved safety, tolerability, duration, and efficacy. We are a team of passionate neuroscience experts with decades of experience within large biopharma (Pfizer, Merck, Regeneron, Biogen ...
WebNov 11, 2024 · About Gilgamesh Pharmaceuticals. Gilgamesh is a pioneering mental health science-focused, early-stage biotechnology company. We have a disciplined focus on developing innovative new chemical ... WebDec 15, 2024 · Gilgamesh Pharmaceuticals, a Clinical stage biotechnology company… Gilgamesh is a pioneering, clinical stage mental health science-focused biotechnology company. We have a disciplined focus on developing innovative new chemical entities (NCEs) leveraging a unique combination of medicinal chemistry, intellectual property …
WebPharmaceutical. Headquarters Regions Greater New York Area, East Coast, Northeastern US. Founded Date Jan 1, 2024. Founders Andrew Kruegel, Dalibor Sames, Jeff Witkin, Jonathan Sporn, Mike Cunningham. … WebJul 18, 2024 · Latest News about Gilgamesh Pharmaceuticals. Recent news which mentions Gilgamesh Pharmaceuticals. Psychedelics Biotech Company Raises $39M …
WebMay 6, 2024 · Gilgamesh Pharmaceuticals, a biotechnology company that uses psychedelic-related drugs to treat neuropsychiatric disorders, reported Thursday it has raised $27 million in a Series A funding round ...
WebGilgamesh currently has three main pharmaceutical pursuits. The first is a 5-HT2A receptor agonist, a non-hallucinogenic serotonergic microdose with low abuse potential that can treat ADHD and mood and anxiety disorders. The second is a “better ketamine:” a safe, non-dissociative, orally-active glutamatergic antagonist to treat mood ... evms pathologists assistantWebJan 22, 2024 · Gilgamesh Pharmaceuticals Share Price and News. Gilgamesh is a serious mental health science focused, preclinical biotechnology company. We... brs classWebDec 15, 2024 · NEW YORK, Dec. 15, 2024 /PRNewswire/ -- Gilgamesh Pharmaceuticals, a biotechnology company developing a portfolio of rapid-acting and durable treatments … evms pathology assistant programWebFeb 3, 2024 · Shares of GW Pharmaceuticals ( GWPH) were skyrocketing 46.3% as of 10:45 a.m. EST on Wednesday. The huge gain came after Jazz Pharmaceuticals ( … evms pathology assistantWebJul 10, 2024 · Stock # of Shares Authorized Par Value Dividend Rate (%) Original Issue Price Liquidation Liquidation Pref. Multiple Conversion Price % Owned; Series B: … brs class 11 dk goelWebDec 15, 2024 · NEW YORK, Dec. 15, 2024 /PRNewswire/ -- Gilgamesh Pharmaceuticals, a biotechnology company developing a portfolio of rapid-acting and durable treatments for depression and other mental health disorders, today announced the closing of a $39 million Series B round of financing. The round was led by Prime Movers Lab with additional … evms payrollWebMay 6, 2024 · News. NEW YORK, May 6, 2024 /PRNewswire/ — Gilgamesh Pharmaceuticals, a mental health science focused biotechnology company utilizing psychedelic-related medicines for the treatment of neuropsychiatric conditions, today announced the closing of a $27 million Series A round of funding led by Prime Movers … evms pccm fellowship